Pediatric BPDCN and Use of Tagraxofusp in Children
This video is part of a larger CE/CME Certified program entitled: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Understanding Disease Biology and Novel Therapeutic Options. You can receive free CME credit, view this video, and download slides from the presentation at MedEdOnTheGo.com
Видео Pediatric BPDCN and Use of Tagraxofusp in Children канала MedEdOTG
Видео Pediatric BPDCN and Use of Tagraxofusp in Children канала MedEdOTG
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
How the Presence of PoPH, With or Without Treatment, Impacts Patients Who Need A Liver Transplant
Should I Use Checkpoint Inhibitors in Advanced NSCLC with Targetable Molecular Alterations?
Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers
Panel Discussion: Challenges and Opportunities to Managing EGFR Exon 20 Mutations
Optimizing ED Triage Strategies for Agitated BD & SCZ Patients
Improving Patient Outcomes: Beneficial & Adverse Effect Profiles of SCZ Antipsychotic Agents
AML Risk Stratification: Cytogenetics and Mutational Analysis - Part 1
Thinking Out of the Box: Monotherapies versus Adjunctive Therapies in Bipolar I and II Depression
Single or Dual Agent IO/Chemotherapy for PD-L1 Negative NSCLC
Case: Aunt Judy Has Been Hallucinating - Treatment Interventions for Parkinson’s Disease Psychosis
You are not alone! Patient Advocacy and Organizations
JAK Inhibition in SR cGVHD: REACH 3, GRAVITAS-309
Which Combination Therapy Do I Choose for Frontline Treatment of MPM?
Bleeds with Vitamin K Antagonist Managed in the ED or ICU
Selecting and Managing RET-Targeted Therapy in mNSCLC
TAAR1: What Is the Role of TAAR1 Agonism for the Treatment of Schizophrenia?
EGFR TKI Resistance: Targeting MET Amplification
How Easy Is It to Use Risk Assessment Algorithms?
When Should I Combine Checkpoint Inhibitors in First-Line Advanced NSCLC?
What’s Next After I Use Checkpoint Inhibitor Combination Therapy First-line in Advanced NSCLC?